必贝特(688759.SH)：BEBT-701临床试验申请获得国家药品监督管理局批准

Core Viewpoint - The company, Bibet (688759.SH), has received approval from the National Medical Products Administration (NMPA) to conduct I-II phase clinical trials for its innovative siRNA drug, BEBT-701, aimed at treating mild to moderate hypertension combined with elevated low-density lipoprotein cholesterol (LDL-C) [1][2] Group 1: Company Developments - BEBT-701 is the first drug developed using the company's proprietary GalNAc dual oligonucleotide conjugate (GDOC) technology platform, designed to silence two key targets, AGT and PCSK9, simultaneously [1] - The drug aims to provide a long-acting, low-frequency administration solution for managing chronic diseases in high cardiovascular risk populations by improving both blood pressure and lipid levels [1] - Non-clinical studies have shown that BEBT-701 effectively and durably silences AGT and PCSK9 in humanized mouse models and non-human primates, demonstrating synergistic effects in lowering blood pressure and lipids with good safety profiles [1] Group 2: Industry Context - According to the World Health Organization's Global Hypertension Report, approximately 1.4 billion people worldwide are affected by hypertension, with around 245 million adults in China suffering from the condition [2] - Hypertension often coexists with high LDL-C, posing significant risks for cardiovascular diseases [2] - siRNA drugs, like BEBT-701, offer a new pathway for managing cardiovascular metabolic diseases by enabling low-frequency, precise, and stable control of treatment, addressing issues related to long-term medication adherence and drug concentration fluctuations [2]